Fusion Pharmaceuticals Inc

Company Profile

Fusion Pharmaceuticals Inc had its IPO on 2016-03-14 under the ticker symbol FUSN.

The company operates in the LIFE SCIENCES sector and (NO DISGNOSTIC SUBSTANCES) industry. Fusion Pharmaceuticals Inc has a staff strength of 0 employees.

Stock update

Shares of Fusion Pharmaceuticals Inc opened at $2.44 at the start of the last trading session i.e. 2022-11-02.

The stocks traded within a range of $2.35 - $2.49, and closed at $2.39.

This is a -3.24% slip from the previous day's closing price.

A total volume of 3,220 shares were traded at the close of the day’s session.

In the last one week, shares of Fusion Pharmaceuticals Inc have increased by +19.5%.

Fusion Pharmaceuticals Inc's Key Ratios

Fusion Pharmaceuticals Inc has a market cap of $0.104 billion, indicating a price to book ratio of 0.55 and a price to sales ratio of 50.0.

In the last 12-months Fusion Pharmaceuticals Inc’s revenue was $0.002 billion with a gross profit of $-0.055 billion and an EBITDA of $-0.076 billion. The EBITDA ratio measures Fusion Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Fusion Pharmaceuticals Inc’s operating margin was -3707% while its return on assets stood at -18.8% with a return of equity of -32.7%.

In Q2, Fusion Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 9.4%.

Fusion Pharmaceuticals Inc’s PE and PEG Ratio

Forward PE

-

Trailing PE

-

PEG

None

Its diluted EPS in the last 12-months stands at $-1.943 per share while it has a forward price to earnings multiple of - and a PEG multiple of None. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Fusion Pharmaceuticals Inc’s profitability.

Fusion Pharmaceuticals Inc stock is trading at a EV to sales ratio of 8.2 and a EV to EBITDA ratio of 0.957. Its price to sales ratio in the trailing 12-months stood at 50.0.

Fusion Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$0.000 billion

Total Liabilities

$0.000 billion

Operating Cash Flow

$0.000 billion

Capital Expenditure

$0.000 billion

Dividend Payout Ratio

0%

Fusion Pharmaceuticals Inc ended 1970 with $0.000 billion in total assets and $131.2 billion in total liabilities. Its intangible assets were valued at $0.000 billion while shareholder equity stood at $0.000 billion.

Fusion Pharmaceuticals Inc ended 1970 with $0.000 billion in deferred long-term liabilities, $0.000 billion in other current liabilities, billion in common stock, $0.000 billion in retained earnings and $0.000 billion in goodwill. Its cash balance stood at $0.000 billion and cash and short-term investments were $0.000 billion. The company’s total short-term debt was $0.000 billion while long-term debt stood at $0.000 billion.

Fusion Pharmaceuticals Inc’s total current assets stands at $0.000 billion while long-term investments were $0.000 billion and short-term investments were $0.000 million. Its net receivables were $0.000 billion compared to accounts payable of $0.000 billion and inventory worth $0.000 billion.

In 1970, Fusion Pharmaceuticals Inc's operating cash flow was $0.000 billion while its capital expenditure stood at $0.000 billion.

Comparatively, Fusion Pharmaceuticals Inc paid $0 billion in dividends in 1970.

Other key metrics

Current Trading Price

$2.39

52-Week High

$8.73

52-Week Low

$1.99

Analyst Target Price

$14.17

Fusion Pharmaceuticals Inc stock is currently trading at $2.39 per share. It touched a 52-week high of $8.73 and a 52-week low of $8.73. Analysts tracking the stock have a 12-month average target price of $14.17.

Its 50-day moving average was $0 and 200-day moving average was $0 The short ratio stood at indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 0% are held by institutions.